Hypoxia-activated prodrug TH-302 decreased survival rate of canine lymphoma cells under hypoxic condition-Reference-Cited by-同舟云学术

Hypoxia-activated prodrug TH-302 decreased survival rate of canine lymphoma cells under hypoxic condition

Published:2017-05-10 Issue:5 Volume:12 Page:e0177305
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Yamazaki Hiroki,Lai Yu-Chang,Tateno Morihiro,Setoguchi Asuka,Goto-Koshino Yuko,Endo Yasuyuki,Nakaichi Munekazu,Tsujimoto Hajime,Miura Naoki^ORCID

Funder

Japan Society for the Promotion of Science

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference36 articles.

1. Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications;D Ito;Vet Immunol Immunopathol,2014

2. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project;AM Perry;Haematologica,2016

3. Canine lymphoma: a review;M Zandvliet;Vet Q,2016

4. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors;Y. Xia;Eur. J Med Chem.,2012

5. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages;KL Talks;Am. J Pathol.,2000

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of hypoxia‐induced metabolism‐associated genes in canine tumours;Veterinary and Comparative Oncology;2024-05-07

2. Influence of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) on Glycolytic Metabolism of Canine Glioma: A Potential Improvement in Cancer Metabolism;Cancers;2023-11-22

3. Assessment of hypoxia-targeting therapy for gastrointestinal lymphoma in dogs: Preclinical test using murine models;Research in Veterinary Science;2023-01

4. Hypoxia‐targeting therapy for intestinal T‐cell lymphoma in dogs: Preclinical study using 3D in vitro models;Veterinary and Comparative Oncology;2022-08-19

5. The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer;Molecular Therapy;2021-06